schizophrenia: search

Mental Health Dangers Of Birth Hypoxia: Lower Levels Of Protein Is Associated With Increased Risk Of Schizophrenia

Complications during pregnancy and birth, such as birth hypoxia - the shortage of oxygen in the body - are associated with an increased risk for schizophrenia. However, it is not clear why hypoxia increases the risk for schizophrenia.

Scientists ID 3 New Candidate Genes for Schizophrenia

FRIDAY, Oct. 24 (HealthDay News) -- American and Dutch researchers believe they may have identified three genes tied to the development of schizophrenia.

Scientists ID 3 New Candidate Genes for Schizophrenia

FRIDAY, Oct. 24 (HealthDay News) -- American and Dutch researchers believe they may have identified three genes tied to the development of schizophrenia.

Scientists ID 3 New Candidate Genes for Schizophrenia

American and Dutch researchers believe they may have identified three genes tied to the development of

Zydus Says Teva Patents Violate Antitrust Laws

Law360, New York (October 28, 2008) -- India-based pharmaceutical company Zydus Cadila’s U.S. subsidiary has filed a lawsuit against Teva Pharmaceutical Industries Ltd., accusing the Israeli generic-drug maker of deceptive trade practices related to the schizophrenia treatment risperidone.

Memory Pharma reveals issuance of US Patent for series of nicotinic alpha-7 receptor agonists - Quick Facts

(RTTNews) - Memory Pharmaceuticals Corp. (MEMY: News ) announced the issuance of U.S. Patent, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia.

Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908

PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908

MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908

MONTVALE, N.J., October 27, 2008 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. today announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908

MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908

MONTVALE, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia (CIAS). The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

Search took 0.02 seconds.